BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Apixaban: Phase III data

The double-blind, international Phase III ADVANCE-3 trial in 3,866 evaluable patients showed that apixaban was superior to Lovenox enoxaparin on the composite primary endpoint of asymptomatic and symptomatic DVT, non-fatal PE or death from any cause at 35 days (1.4% vs. 3.9%, p<0.001). Apixaban was also superior to Lovenox on the composite secondary endpoint of asymptomatic or symptomatic proximal DVT, non-fatal PE or death related to VTE (0.5%...

Read the full 337 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >